{
    "organizations": [],
    "uuid": "4c22600a712c21ec37aec553b1a4dca2dd96736e",
    "author": "",
    "url": "https://www.reuters.com/article/brief-glaukos-submits-ide-application-to/brief-glaukos-submits-ide-application-to-fda-to-study-istent-infinite-trabecular-micro-bypass-system-idUSASB0BZJD",
    "ord_in_thread": 0,
    "title": "BRIEF-Glaukos Submits IDE Application To FDA To Study iStent Infinite Trabecular Micro-Bypass System",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 12 PM / Updated 12 minutes ago BRIEF-Glaukos Submits IDE Application To FDA To Study iStent Infinite Trabecular Micro-Bypass System Reuters Staff \nJan 3 (Reuters) - Glaukos Corp: \n* GLAUKOS SUBMITS IDE APPLICATION TO FDA TO STUDY ISTENT INFINITE™ TRABECULAR MICRO-BYPASS SYSTEM \n* GLAUKOS CORP - ‍SUBMITTED IDE APPLICATION TO FDA SEEKING AUTHORIZATION TO STUDY ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-03T14:12:00.000+02:00",
    "crawled": "2018-01-03T14:29:15.042+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "submits",
        "ide",
        "application",
        "fda",
        "study",
        "istent",
        "infinite",
        "trabecular",
        "system",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "glaukos",
        "corp",
        "glaukos",
        "submits",
        "ide",
        "application",
        "fda",
        "study",
        "istent",
        "trabecular",
        "system",
        "glaukos",
        "corp",
        "ide",
        "application",
        "fda",
        "seeking",
        "authorization",
        "study",
        "istent",
        "infinite",
        "trabecular",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}